Libin Shi, MD, PhD

Director of Research


Dr. Libin Shi earned her PhD in Biochemistry and Molecular Biology after graduated with Master degree in Medical Microbiology from Dalian Medical University. She also had her M.D. from the same university. She did her postdoctoral training and then worked as a Research Scientist at Colorado State University.  Her previous research was focused on developing novel biomarkers for tuberculosis diagnosis and identification of mycobacterial drug targets.  Dr. Shi played a critical leadership role in daily laboratory research after she joined Immunoah Therapeutics, Inc. as a Director of Research.

Min Wang, MD

Founder and Chairman

Dr. Wang graduated from Beijing Medical University, received his postdoctorate research fellowship training in immunology from Washington University School of Medicine in St. Louis, and received his resident physician training from the University of Minnesota School of Medicine. He holds medical licenses in California and Colorado with clinical expertise in anesthesiology, pain medicine and critical care. Dr. Wang is also the founders of several biotech startups, including Beijing ATGC Gene Tech Corp, one of the leading clinical diagnostic companies providing services in personalized medicine. He serves as Chief Medical Officer in Shanghai Syndegen Biotechnology Co. and Quintara Discovery. 


‚Äč

about Us

          Immunoah Therapeutics, Inc. is a biotech startup company  focusing on the discovery, development, and commercialization of novel therapeutic monoclonal antibodies and their applications in cancer immunotherapies. Our lead product candidate, Zymwolumab, is a group of proprietary agonist antibodies, which demonstrated potent immunological enhancement and anticancer effects. A PCT filing was completed and its right in the region of China was licensed out to a pharmaceutical company in 2017.